We develop standards, methods, tools and technology to advance the reliability of genomic measurements for use in biotechnology including genome editing, human genome sequencing and bioinformatics, cancer genomics, and metagenomics. For example, NIST scientists led the development of the world's first and only whole genome reference materials, authoritatively characterized by the NIST-led Genome in a Bottle Consortium; these human genomes provide laboratories with the capability to accurately “map” DNA for genetic testing, benchmark sequencing technologies and bioinformatics, and develop new medical diagnostics and future customized drug therapies. The NIST-led Genome Editing Consortium aims to address the measurements and standards needed to increase confidence and lower the risk of utilizing genome editing technologies in research and commercial products. NIST's cancer biomarker reference materials help researchers and clinicians establish analytical validation of their measurement processes.
Current Activities and Products
Genome Editing Consortium – measurement solutions and standards to support innovation and products in the genome editing technology space